Cargando…

Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy

There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Xiaona, Wang, Dan, Zhang, Wenjing, Liu, Jinshuang, Liu, Chao, Li, Qingwei, Ma, Zhigang, Li, Hengzhen, Guan, Xin, Bai, Yibing, Yang, Jiani, Lou, Changjie, Li, Xiaobo, Wang, Guangyu, Li, Zhiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005614/
https://www.ncbi.nlm.nih.gov/pubmed/33791296
http://dx.doi.org/10.3389/fcell.2021.638312
_version_ 1783672146446254080
author Fan, Xiaona
Wang, Dan
Zhang, Wenjing
Liu, Jinshuang
Liu, Chao
Li, Qingwei
Ma, Zhigang
Li, Hengzhen
Guan, Xin
Bai, Yibing
Yang, Jiani
Lou, Changjie
Li, Xiaobo
Wang, Guangyu
Li, Zhiwei
author_facet Fan, Xiaona
Wang, Dan
Zhang, Wenjing
Liu, Jinshuang
Liu, Chao
Li, Qingwei
Ma, Zhigang
Li, Hengzhen
Guan, Xin
Bai, Yibing
Yang, Jiani
Lou, Changjie
Li, Xiaobo
Wang, Guangyu
Li, Zhiwei
author_sort Fan, Xiaona
collection PubMed
description There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced gastric and colorectal cancer. Data for 111 patients with advanced gastric and colorectal cancer treated with anti–PD-1 regimens were retrospectively analyzed. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and clinical characteristics of each patient were selected as the main variables. Overall response rate, disease control rate, and progression-free survival were primary endpoints, and overall survival and immune-related adverse events (irAEs) were secondary endpoints. The chi-squared test and Fisher’s exact test were used to evaluate relationships between categorical variables. Uni- and multivariate Cox regression analyses were performed, and median progression-free survival and overall survival were estimated with the Kaplan–Meier method. The overall response rate and disease control rate of anti–PD-1therapy in advanced gastric and colorectal tumors were 12.61 and 66.66%, respectively. The patients with MLR < 0.31, NLR < 5, and PLR < 135 had a significantly higher disease control rate than those with MLR > 0.31, NLR > 5, and PLR > 135 (P < 0.05). The multivariate analysis revealed that MLR < 0.31, BMI > 18.5, and anti–PD-1 therapy in first-line were associated with prolonged PFS. MLR < 0.31 and BMI > 18.5 were associated with prolonged overall survival. The irAE rate differed significantly between PLR groups, and PLR < 135 was associated with an increased rate of irAEs (P = 0.028). These results indicate that the inflammatory markers NLR, MLR, and PLR have clinical utility for predicting survival or risk of irAEs in patients with advanced gastric cancer and colorectal cancer.
format Online
Article
Text
id pubmed-8005614
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80056142021-03-30 Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy Fan, Xiaona Wang, Dan Zhang, Wenjing Liu, Jinshuang Liu, Chao Li, Qingwei Ma, Zhigang Li, Hengzhen Guan, Xin Bai, Yibing Yang, Jiani Lou, Changjie Li, Xiaobo Wang, Guangyu Li, Zhiwei Front Cell Dev Biol Cell and Developmental Biology There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced gastric and colorectal cancer. Data for 111 patients with advanced gastric and colorectal cancer treated with anti–PD-1 regimens were retrospectively analyzed. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and clinical characteristics of each patient were selected as the main variables. Overall response rate, disease control rate, and progression-free survival were primary endpoints, and overall survival and immune-related adverse events (irAEs) were secondary endpoints. The chi-squared test and Fisher’s exact test were used to evaluate relationships between categorical variables. Uni- and multivariate Cox regression analyses were performed, and median progression-free survival and overall survival were estimated with the Kaplan–Meier method. The overall response rate and disease control rate of anti–PD-1therapy in advanced gastric and colorectal tumors were 12.61 and 66.66%, respectively. The patients with MLR < 0.31, NLR < 5, and PLR < 135 had a significantly higher disease control rate than those with MLR > 0.31, NLR > 5, and PLR > 135 (P < 0.05). The multivariate analysis revealed that MLR < 0.31, BMI > 18.5, and anti–PD-1 therapy in first-line were associated with prolonged PFS. MLR < 0.31 and BMI > 18.5 were associated with prolonged overall survival. The irAE rate differed significantly between PLR groups, and PLR < 135 was associated with an increased rate of irAEs (P = 0.028). These results indicate that the inflammatory markers NLR, MLR, and PLR have clinical utility for predicting survival or risk of irAEs in patients with advanced gastric cancer and colorectal cancer. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005614/ /pubmed/33791296 http://dx.doi.org/10.3389/fcell.2021.638312 Text en Copyright © 2021 Fan, Wang, Zhang, Liu, Liu, Li, Ma, Li, Guan, Bai, Yang, Lou, Li, Wang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Fan, Xiaona
Wang, Dan
Zhang, Wenjing
Liu, Jinshuang
Liu, Chao
Li, Qingwei
Ma, Zhigang
Li, Hengzhen
Guan, Xin
Bai, Yibing
Yang, Jiani
Lou, Changjie
Li, Xiaobo
Wang, Guangyu
Li, Zhiwei
Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title_full Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title_fullStr Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title_full_unstemmed Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title_short Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
title_sort inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti–pd-1 therapy
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005614/
https://www.ncbi.nlm.nih.gov/pubmed/33791296
http://dx.doi.org/10.3389/fcell.2021.638312
work_keys_str_mv AT fanxiaona inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT wangdan inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT zhangwenjing inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT liujinshuang inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT liuchao inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT liqingwei inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT mazhigang inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT lihengzhen inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT guanxin inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT baiyibing inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT yangjiani inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT louchangjie inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT lixiaobo inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT wangguangyu inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy
AT lizhiwei inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy